Despite the supply-chain issues that have plagued companies around the world, Davis said Merck was able to make 10 million courses of the drug, molnupiravir, as expected last year. They just need to be labeled and shipped, he said.
“We’re confident we’re going to deliver the product,” Davis said in an interview with
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.